{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:08:04Z","timestamp":1758272884633},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T00:00:00Z","timestamp":1375660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0070611","type":"journal-article","created":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T21:42:56Z","timestamp":1375738976000},"page":"e70611","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"umin000001102","registry":"10.18810\/umin-japan"}],"author":[{"given":"Junko","family":"Tanuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuji","family":"Teruya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhito","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Yazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihisa","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,8,5]]},"reference":[{"key":"ref1","first-page":"603","article-title":"AmericanThoracicSociety\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"6","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","unstructured":"Pfizer, Inc. Mycobutin (rifabutin) prescribing information. Pfizer, Inc., New York, NY. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.pfizer.com\/files\/products\/uspi_mycobutin.pdf\" xlink:type=\"simple\">http:\/\/www.pfizer.com\/files\/products\/uspi_mycobutin.pdf<\/ext-link>. Accessed 2012 August 21."},{"key":"ref3","first-page":"1","article-title":"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents","volume":"58","year":"2009","journal-title":"MMWR"},{"key":"ref4","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf<\/ext-link>. Accessed 2012 August 21."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0091270003262807","article-title":"Indinavir and rifabutin drug interactions in healthy volunteers","volume":"44","author":"WK Kraft","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1128\/AAC.00724-07","article-title":"Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects","volume":"52","author":"SL Ford","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/606056","article-title":"Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis","volume":"49","author":"C Boulanger","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/AAC.00992-10","article-title":"Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects","volume":"55","author":"X Zhang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref9","first-page":"658","article-title":"Uveitis associated with rifabutin therapy","volume":"43","year":"1994","journal-title":"MMWR"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1086\/517366","article-title":"Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for <italic>Mycobacterium avium<\/italic> complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group","volume":"177","author":"SD Shafran","year":"1998","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/jac\/dkr266","article-title":"Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir","volume":"66","author":"J Zhang","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1128\/AAC.01749-09","article-title":"Pharmacokinetics of darunavir\/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers","volume":"54","author":"V Sekar","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3: 1\u2013139. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf<\/ext-link>. Accessed 2012 August 21."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"M Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/598336","article-title":"Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy","volume":"48","author":"ER Jenny-Avital","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1086\/430377","article-title":"Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City. 1997\u20132000","volume":"41","author":"J Li","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/dkp263","article-title":"Pharmacokinetic interactions between rifabutin and lopinavir\/ritonavir in HIV-infected patients with mycobacterial co-infection","volume":"64","author":"H Khachi","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/clpt.2009.2","article-title":"Pharmacoepigenetics: its role in interindividual differences in drug response","volume":"85","author":"A Gomez","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s12272-011-1103-2","article-title":"Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes","volume":"34","author":"IS Lee","year":"2011","journal-title":"Arch Pharm Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22","author":"CM Kunin","year":"1996","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1128\/AAC.33.8.1237","article-title":"Pharmacokinetics of rifabutin","volume":"33","author":"MH Skinner","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","article-title":"The clinical pharmacokinetics of rifabutin","volume":"22","author":"TF Blaschke","year":"1996","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3109\/00498259009046832","article-title":"Autoinduction of rifabutin metabolism in man","volume":"20","author":"M Strolin Benedetti","year":"1990","journal-title":"Xenobiotica"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Tuberculosis Trials Consortium","volume":"167","author":"M Weiner","year":"2003","journal-title":"Am J Respir Crit Care Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0070611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:27:05Z","timestamp":1589002025000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0070611"}},"subtitle":[],"editor":[{"given":"Omar","family":"Sued","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,5]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0070611","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,5]]}}}